MO SB1223

Products that act as or could potentially act as gene therapy must be conspicuously labeled "Potential Gene Therapy Product" or "Gene Therapy Product" if known, applying to foods, cosmetics, and substances intended for human use or physiological effects

Missouri residents may submit written requests to any entity producing, selling, or distributing products capable of infecting individuals with disease or exposing them to genetically modified material (including vaccines, gene therapies, and drugs) for information on secondary exposure risks

Entities receiving disclosure requests must respond within 21 days with all relevant reports, research, and knowledge about how non-users may be exposed to the product

Products that could infect, transmit to, or be absorbed by individuals in ways acting as medical interventions, vaccines, drugs, or genetic modifications require fully informed consent from all potentially exposed individuals before exposure occurs

Fully informed consent must include disclosure of all benefits, risks, side effects, adverse events of special interest, and other reasonably possible impacts of the product